These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7648234)

  • 1. Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia.
    Kehely A; MacMahon M; Barbir M; Wray R; Hunt BJ; Prescott RJ; Thompson GR
    QJM; 1995 Jun; 88(6):421-7. PubMed ID: 7648234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effectiveness, tolerance and safety of simvastatin in comparison with bezafibrate in treatment of hypercholesterolemia].
    Lechleitner M; Sailer S; Irsigler H; Klein W; Patsch JR
    Wien Med Wochenschr; 1995; 145(21):577-83. PubMed ID: 8560901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of primary hypercholesterolaemia with simvastatin. New Zealand multicentre evaluation.
    Lintott CJ; Scott RS; Sharpe DN; Nye ER; Charleson H; French JK; White HD; Reuben S; Maling TJ; Lewis GR
    Med J Aust; 1991 Oct; 155(7):433-6. PubMed ID: 1921811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The comparative treatment with lovastatin and bezafibrate of primary hypercholesterolemia. A randomized and double-blind trial].
    Sánchez Domínguez J; Rodríguez Padial L; Navarro A; Barcina C; Fernández E; Rivera G; Cuesta L; Lázaro-Carrasco E
    Rev Esp Cardiol; 1991 Apr; 44(4):251-7. PubMed ID: 2068368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison about the efficacy and tolerability between simvastatin and bezafibrate in the treatment of hypercholesterolemia].
    Bruckert E; Truffert J; De Gennes JL
    Ann Med Interne (Paris); 1991; 142(7):505-10. PubMed ID: 1789528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).
    Grundy SM; Vega GL; Yuan Z; Battisti WP; Brady WE; Palmisano J
    Am J Cardiol; 2005 Feb; 95(4):462-8. PubMed ID: 15695129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
    Hoogerbrugge N; Jansen H; De Heide L; Zillikens MC; Deckers JW; Birkenhäger JC
    J Intern Med; 1997 Feb; 241(2):151-5. PubMed ID: 9077372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
    Cortellaro M; Cofrancesco E; Boschetti C; Cortellaro F; Mancini M; Mariani M; Paoletti R
    Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.
    Mohiuddin SM; Pepine CJ; Kelly MT; Buttler SM; Setze CM; Sleep DJ; Stolzenbach JC
    Am Heart J; 2009 Jan; 157(1):195-203. PubMed ID: 19081418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety and tolerability of lovastatin and bezafibrate retard in patients with hypercholesterolemia.
    Schumacher M; Eber B; Silberbauer K; Breier C; Stühlinger W; Schmidt P; Gaul G; Klein W
    Acta Med Austriaca; 1992; 19(5):140-4. PubMed ID: 1298143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).
    Ballantyne CM; Davidson MH; McKenney J; Keller LH; Bajorunas DR; Karas RH
    Am J Cardiol; 2008 May; 101(10):1428-36. PubMed ID: 18471454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia.
    Farnier M; Bonnefous F; Debbas N; Irvine A
    Arch Intern Med; 1994 Feb; 154(4):441-9. PubMed ID: 8117177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study.
    Akçiçek F; Ok E; Duman S; Kürsad S; Unsal A; Alev M; Atabay G; Basçi A
    Adv Perit Dial; 1996; 12():261-5. PubMed ID: 8865916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia.
    Frohlich J; Brun LD; Blank D; Campeau L; Crockford P; Curnew G; Dafoe W; Davignon J; Dufour R; Emery G
    Can J Cardiol; 1993 Jun; 9(5):405-12. PubMed ID: 8348392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effect of simvastatin in patients with drug resistant familial hypercholesterolaemia.
    Lewis-Barned NJ; Ball MJ
    N Z Med J; 1992 Jul; 105(938):284-6. PubMed ID: 1495661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
    Grundy SM; Vega GL; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2009 Aug; 104(4):548-53. PubMed ID: 19660610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
    May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
    Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
    Constantinides A; de Vries R; van Leeuwen JJ; Gautier T; van Pelt LJ; Tselepis AD; Lagrost L; Dullaart RP
    Eur J Intern Med; 2012 Oct; 23(7):633-8. PubMed ID: 22902096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.